{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:52:20Z","timestamp":1791503540619,"version":"4.3.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.resinv.2026.101494","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:30:37Z","timestamp":1785209437000},"page":"101494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of drug-induced interstitial lung disease in the era of evolving lung cancer therapies: A mini-review"],"prefix":"10.1016","volume":"64","author":[{"given":"Taeka","family":"Naraoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-5878","authenticated-orcid":false,"given":"Toshiyuki","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2026.101494_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.resinv.2026.101494_bib2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1148\/radiol.2021203427","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the fleischner society","volume":"298","author":"Johkoh","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.resinv.2026.101494_bib3","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s40264-020-00968-7","article-title":"Interstitial lung disease as an adverse drug reaction in Japan: exploration of regulatory actions as a basis for high reporting","volume":"43","author":"Iwasa","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.resinv.2026.101494_bib4","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101494_bib5","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jjco\/hyt049","article-title":"Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405)","volume":"43","author":"Akamatsu","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib7","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.jtho.2020.08.025","article-title":"Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with osimertinib in Japan","volume":"15","author":"Gemma","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.resinv.2026.101494_bib9","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2169\/internalmedicine.56.7464","article-title":"Interstitial lung disease after pleurodesis for malignant pleural effusion","volume":"56","author":"Yokoe","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2026.101494_bib10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/resp.13192","article-title":"Old age and underlying interstitial abnormalities are risk factors for development of ARDS after pleurodesis using limited amount of large particle size talc","volume":"23","author":"Shinno","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2026.101494_bib11","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.3390\/ijms20164021","article-title":"Blockade of EGFR activation promotes TNF-induced lung epithelial cell apoptosis and pulmonary injury","volume":"20","author":"Yamaoka","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.resinv.2026.101494_bib12","doi-asserted-by":"crossref","first-page":"9101","DOI":"10.1074\/jbc.M114.631580","article-title":"Gefitinib-mediated reactive oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer cells","volume":"290","author":"Okon","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.resinv.2026.101494_bib13","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/ijms22020792","article-title":"Molecular and clinical features of EGFR-TKI-associated lung injury","volume":"22","author":"Ohmori","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.resinv.2026.101494_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2018.06.032","article-title":"Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC","volume":"123","author":"Suh","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2026.101494_bib15","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1097\/JTO.0b013e3182598abb","article-title":"Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR)","volume":"7","author":"Nakagawa","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101494_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1652750","article-title":"Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study","volume":"16","author":"Miao","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.resinv.2026.101494_bib18","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdw647","article-title":"High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy","volume":"28","author":"Kotake","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101494_bib21","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.3390\/cancers14194642","article-title":"Radiation recall pneumonitis: a rare syndrome that should be recognized","volume":"14","author":"Jan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.resinv.2026.101494_bib22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jtho.2018.11.022","article-title":"Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib","volume":"14","author":"Gemma","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib23","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/cas.13977","article-title":"Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan","volume":"110","author":"Masuda","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.resinv.2026.101494_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005323","article-title":"Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis","volume":"10","author":"Franken","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.resinv.2026.101494_bib25","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1007\/s00432-023-04696-0","article-title":"Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis","volume":"149","author":"Wang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66509-x","article-title":"Uncovering the immune mechanisms underlying the emergence of immunotherapy-induced pneumonitis in lung cancer patients","volume":"16","author":"Lin","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.resinv.2026.101494_bib27","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1172\/JCI128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"Suresh","year":"2019","journal-title":"J Clin Investig"},{"key":"10.1016\/j.resinv.2026.101494_bib28","article-title":"Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: diagnosis, mechanism, and treatment strategies","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2026.101494_bib29","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1038\/s41388-023-02805-4","article-title":"Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis","volume":"42","author":"Cui","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.resinv.2026.101494_bib30","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib32","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2018.09.015","article-title":"Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","volume":"125","author":"Cho","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2026.101494_bib34","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101494_bib35","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/1759-7714.13187","article-title":"High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer","volume":"10","author":"Tone","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.resinv.2026.101494_bib36","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cllc.2019.07.006","article-title":"Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors","volume":"20","author":"Fukihara","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.resinv.2026.101494_bib37","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib38","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3390\/cancers16112159","article-title":"Real-world prevalence and tolerability of immune-related adverse events in older adults with non-small cell lung cancer: a multi-institutional retrospective study","volume":"16","author":"Matsukane","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.resinv.2026.101494_bib39","article-title":"Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2026.101494_bib40","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.23.00013","article-title":"Antibody-drug conjugates in lung cancer: recent advances and implementing strategies","volume":"41","author":"Passaro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib41","first-page":"165","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.resinv.2026.101494_bib42","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.resinv.2026.101494_bib43","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101494_bib44","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib45","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.resinv.2026.101494_bib47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12931-019-1204-x","article-title":"Chemical pleurodesis\u2014a review of mechanisms involved in pleural space obliteration","volume":"20","author":"Mierzejewski","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2026.101494_bib48","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-5223(19)37535-X","article-title":"Adult respiratory distress syndrome following intrapleural instillation of talc","volume":"85","author":"Rinaldo","year":"1983","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.resinv.2026.101494_bib49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0002-9610(99)00075-6","article-title":"Respiratory failure following talc pleurodesis","volume":"177","author":"Rehse","year":"1999","journal-title":"Am J Surg"},{"key":"10.1016\/j.resinv.2026.101494_bib50","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1164\/rccm.200311-1579OC","article-title":"Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size","volume":"170","author":"Maskell","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101494_bib51","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(07)60708-9","article-title":"Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study","volume":"369","author":"Janssen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2026.101494_bib52","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jjco\/hyy020","article-title":"Sterilized talc pleurodesis for malignant pleural effusions: a Phase II study for investigational new drug application in Japan","volume":"48","author":"Saka","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/clin.1996.0040","article-title":"Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo","volume":"78","author":"Kitsuki","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.resinv.2026.101494_bib54","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.2169\/internalmedicine.51.8315","article-title":"Intrathoracic administration of OK-432 elevates the serum procalcitonin levels","volume":"51","author":"Ogasawara","year":"2012","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2026.101494_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108590","article-title":"Risk of lung injury with immune checkpoint inhibitors after talc pleurodesis: a retrospective study","volume":"204","author":"Tanaka","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2026.101494_bib56","first-page":"126","article-title":"Amivantamab plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC","volume":"390","author":"Zhou","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101494_bib57","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101494_bib58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000079633","article-title":"Interstitial lung disease induced by drugs and radiation","volume":"71","author":"Camus","year":"2004","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2026.101494_bib59","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo","year":"2013","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2026.101494_bib60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000548862","article-title":"Drug-induced interstitial lung disease in lung cancer patients","volume":"105","author":"Vanhandsaeme","year":"2025","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2026.101494_bib61","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.resinv.2026.101494_bib62","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0012-2019","article-title":"Management of pulmonary toxicity associated with immune checkpoint inhibitors","volume":"28","author":"Delaunay","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2026.101494_bib63","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib64","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2213-2600(19)30342-X","article-title":"Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study","volume":"8","author":"Troy","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2026.101494_bib65","series-title":"Common terminology criteria for adverse events (CTCAE)","year":"2017"},{"key":"10.1016\/j.resinv.2026.101494_bib66","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2026.101494_bib68","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40261-024-01400-z","article-title":"Diagnosis and management of drug-induced interstitial lung disease in the context of anti-cancer therapy: a multidisciplinary viewpoint by Portuguese experts","volume":"44","author":"Fontes","year":"2024","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.resinv.2026.101494_bib69","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1183\/23120541.00553-2025","article-title":"Patient education and self-management in interstitial lung disease: why and what, now how?","volume":"11","author":"Khor","year":"2025","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2026.101494_bib70","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40780-024-00373-7","article-title":"Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study","volume":"10","author":"Yokoi","year":"2024","journal-title":"J Pharm Health Care Sci"},{"key":"10.1016\/j.resinv.2026.101494_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102043","article-title":"Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients","volume":"8","author":"Wekking","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.resinv.2026.101494_bib72","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40264-023-01328-x","article-title":"Clinical guidance on the monitoring and management of trastuzumab deruxtecan (T-DXd)-related adverse events: insights from an Asia-Pacific multidisciplinary panel","volume":"46","author":"Chiu","year":"2023","journal-title":"Drug Saf"},{"key":"10.1016\/j.resinv.2026.101494_bib73","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11523-024-01048-x","article-title":"Real-world data on subsequent therapy for first-line osimertinib-induced pneumonitis: safety of EGFR-TKI rechallenge (Osi-risk study TORG-TG2101)","volume":"19","author":"Nishioka","year":"2024","journal-title":"Targeted Oncol"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526001280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526001280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:25:06Z","timestamp":1791501906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534526001280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2212534526001280"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101494","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of drug-induced interstitial lung disease in the era of evolving lung cancer therapies: A mini-review","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101494"}}